ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

1-Ethyl-3-(3'-dimethylaminopropyl)carbodiimide → 1-[(R)-3-(2-{4-[1-(2-Ethoxy-ethyl)-1H-benzoimidazol-2-yl]-[1,4]diazepan-1-yl}-ethyl)-3-phenyl-pyrrolidin-1-yl]-1-[2-methoxy-5-(3-methylsulfanyl-[1,2,4]triazol-4-yl)-phenyl]-methanone

HRID 2230745
ノート
印刷プレビュー

反応式

HRID 2230745 の反応式
[CH3:1][O:2][C:3]1[CH:11]=[CH:10][C:9]([N:12]2[CH:16]=[N:15][N:14]=[C:13]2[S:17][CH3:18])=[CH:8][C:4]=1[C:5]([OH:7])=O.Cl.Cl.[CH2:21]([O:23][CH2:24][CH2:25][N:26]1[C:30]2[CH:31]=[CH:32][CH:33]=[CH:34][C:29]=2[N:28]=[C:27]1[N:35]1[CH2:41][CH2:40][CH2:39][N:38]([CH2:42][CH2:43][C@:44]2([C:49]3[CH:54]=[CH:53][CH:52]=[CH:51][CH:50]=3)[CH2:48][CH2:47][NH:46][CH2:45]2)[CH2:37][CH2:36]1)[CH3:22].O.ON1C2C=CC=CC=2N=N1.CN(C)CCCN=C=NCC.C(N(C(C)C)CC)(C)C>ClCCl>[CH2:21]([O:23][CH2:24][CH2:25][N:26]1[C:30]2[CH:31]=[CH:32][CH:33]=[CH:34][C:29]=2[N:28]=[C:27]1[N:35]1[CH2:41][CH2:40][CH2:39][N:38]([CH2:42][CH2:43][C@:44]2([C:49]3[CH:54]=[CH:53][CH:52]=[CH:51][CH:50]=3)[CH2:48][CH2:47][N:46]([C:5]([C:4]3[CH:8]=[C:9]([N:12]4[CH:16]=[N:15][N:14]=[C:13]4[S:17][CH3:18])[CH:10]=[CH:11][C:3]=3[O:2][CH3:1])=[O:7])[CH2:45]2)[CH2:37][CH2:36]1)[CH3:22]
参加物実験手順後処理出典と根拠反応ノート

参加物

7

反応物 5

HCID 159081-Ethyl-3-(3'-dimethylaminopropyl)carbodiimideHCID 81531DiisopropylethylamineHCID 27960291-Hydroxybenzotriazole hydrateHCID 184647022-Methoxy-5-(3-methylsulfanyl-[1,2,4]triazol-4-yl)-benzoic acidHCID 701481071-(2-ethoxy-ethyl)-2-{4-[2-((S)-3-phenyl-pyrrolidin-3-yl)-ethyl]-[1,4]diazepan-1-yl}-1H-benzoimidazole dihydrochloride

生成物 1

HCID 59902268
1-[(R)-3-(2-{4-[1-(2-Ethoxy-ethyl)-1H-benzoimidazol-2-yl]-[1,4]diazepan-1-yl}-ethyl)-3-phenyl-pyrrolidin-1-yl]-1-[2-methoxy-5-(3-methylsulfanyl-[1,2,4]triazol-4-yl)-phenyl]-methanone
収率 17.1%

試薬・触媒・溶媒 1

HCID 6344Dichloromethane溶媒

実験手順

To a mixture of 2-methoxy-5-(3-methylsulfanyl-[1,2,4]triazol-4-yl)-benzoic acid (0.27 g, 0.42 mmol), 1-(2-ethoxy-ethyl)-2-{4-[2-((S)-3-phenyl-pyrrolidin-3-yl)-ethyl]-[1,4]diazepan-1-yl}-1H-benzoimidazole dihydrochloride (0.23 g, 0.42 mmol), 1-hydroxybenzotriazole hydrate (0.068 g, 0.51 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (0.97 g, 0.51 mmol), add via syringe under argon anhydrous dichloromethane (15 mL). Add diisopropylethylamine (0.22 mL, 1.26 mmol) and stir at room temperature for 20 hours. Dilute with dichloromethane and wash twice with water. Wash with saturated NaHCO3 solution, dry (MgSO4) the organic phase, filter and concentrate to an oil. Purify the oil by flash chromatography (silica gel, 3.5×15.2 cm) eluting with dichloromethane and then with 10% methanol in dichloromethane. Concentrate the appropriate fractions to afford 0.051 g of the title compound, Rf=0.26 (silica gel, 10% methanol in dichloromethane). The compound may be converted to the dihydrochloride salt by methods well known in the art.

後処理

  1. additionadd via syringe under argon anhydrous dichloromethane (15 mL)
  2. washwash twice with water
  3. washWash with saturated NaHCO3 solution
  4. dry with materialdry (MgSO4) the organic phase
  5. filtrationfilter
  6. concentrationconcentrate to an oil
  7. customPurify the oil by flash chromatography (silica gel, 3.5×15.2 cm)
  8. washeluting with dichloromethane
  9. concentrationConcentrate the appropriate fractions

出典と根拠

ORDレコード
ord-25f6f960a2814cbebafb0ced7bc99a60
出典データセット
uspto-grants-2002_07
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US06423704B1

反応ノート

読み込み中…

このページの内容参加物実験手順後処理出典と根拠反応ノート